The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned. There has been no safety concern with the use of leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, Feb. 17, 2025 /PRNewswire/ -- Foresee...
Hence then, the article about foresee pharmaceuticals receives the third positive recommendation from the dsmb to continue the casppian study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Receives the Third Positive Recommendation from the DSMB to Continue the Casppian Study )
Also on site :
- Nike’s ‘Walkers Tolerated’ sign at the Boston Marathon was meant to fire up runners. Instead, it insulted them
- 'DWTS' Judge Carrie Ann Inaba Speaks Out After Medical Emergency on Plane (Exclusive)
- Billionaire Connie Ballmer just donated $80 million to support NPR after Trump cut $1.1 billion from public broadcasting